Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alliance for Clinical Trials in Oncology
With
National Cancer Institute (NCI)
OBJECTIVES:
* Determine the response rate and time to progression in patients with relapsed or refractory intermediate or high grade non-Hodgkin's lymphoma treated with doxorubicin and topotecan.
* Determine the toxicity of this regimen in these patients.
OUTLINE: Patients receive doxorubicin IV over 5-10 minutes on day 1 and topotecan IV over 30 minutes on days 3-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression.
Patients are followed every 6 months for 2 years and annually for the next 3 years.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
DISEASE CHARACTERISTICS:
Histologically confirmed recurrent or refractory non-Hodgkin's lymphoma of one of the following subtypes:
* Follicular center lymphoma, grade 3
* Diffuse large B-cell lymphoma
* Diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma
* Burkitt's lymphoma
* High grade B-cell lymphoma, Burkitt-like
* Anaplastic large cell lymphoma, CD30+ cell type
* Anaplastic large cell lymphoma, T-cell type
* Anaplastic large cell lymphoma, null-cell type
* Anaplastic large cell lymphoma, Hodgkin's like
Bidimensionally measurable disease NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.
PATIENT CHARACTERISTICS:
Age:
Any age
Performance status:
Not specified
Life expectancy:
Not specified
Hematopoietic:
Absolute neutrophil count at least 1,500/mm3
Platelet count at least 100,000/mm3
Hepatic:
Bilirubin no greater than 2.0 mg/dL history of Gilbert's Disease
AST no greater than 2.5 times upper limit of normal
Renal:
Creatinine normal
Cardiovascular:
LVEF at least 45% by MUGA or echocardiogram
Other:
Not pregnant or nursing
Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Not specified
Chemotherapy:
Greater than 3 weeks since prior chemotherapy (6 weeks since prior nitrosoureas or mitomycin)
No greater than 96 mg/m2 mitoxantrone
No greater than 400 mg/m2 prior doxorubicin or combined total doxorubicin and mitoxantrone
No prior camptothecins
No other concurrent chemotherapy
Endocrine therapy:
No concurrent hormonal therapy except steroids for adrenal failure or hormones given for nondisease conditions (e.g., insulin for diabetes)
No concurrent dexamethasone or other steroidal antiemetics
Radiotherapy:
Greater than 3 weeks since prior radiotherapy
No concurrent radiotherapy except whole brain irradiation for documented CNS disease
Surgery:
Not specified
Clareo Health | Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
